Education
About Us
Working with TipRanks
Follow Us
Soligenix Inc (SNGX)
:SNGX
SNGX Stock Chart & Stats
$1.70
-$0.10(-2.65%)
At close: 4:00 PM EST
$1.70
-$0.10(-2.65%)
Day’s Range― - ―
52-Week Range$1.09 - $6.23
Previous CloseN/A
Volume55.16K
Average Volume (3M)2.03M
Market Cap
$16.76M
Enterprise Value-$391.20K
Total Cash (Recent Filing)$5.10M
Total Debt (Recent Filing)$411.40K
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Nov 07, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding9,861,130
10 Day Avg. Volume3,049,184
30 Day Avg. Volume2,025,795
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.02
Enterprise Value/Revenue61.59
Enterprise Value/Gross Profit-1.42K
Enterprise Value/Ebitda0.03
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Soligenix News
SNGX FAQ
What was Soligenix Inc’s price range in the past 12 months?
Soligenix Inc lowest stock price was $1.09 and its highest was $6.23 in the past 12 months.
What is Soligenix Inc’s market cap?
Soligenix Inc’s market cap is $16.76M.
When is Soligenix Inc’s upcoming earnings report date?
Soligenix Inc’s upcoming earnings report date is Nov 07, 2025 which is in 17 days.
How were Soligenix Inc’s earnings last quarter?
Soligenix Inc released its earnings results on Aug 14, 2025. The company reported -$0.82 earnings per share for the quarter, beating the consensus estimate of -$0.92 by $0.1.
Is Soligenix Inc overvalued?
According to Wall Street analysts Soligenix Inc’s price is currently Overvalued.
Does Soligenix Inc pay dividends?
Soligenix Inc does not currently pay dividends.
What is Soligenix Inc’s EPS estimate?
Soligenix Inc’s EPS estimate is -0.56.
How many shares outstanding does Soligenix Inc have?
Soligenix Inc has 9,861,130 shares outstanding.
What happened to Soligenix Inc’s price movement after its last earnings report?
Soligenix Inc reported an EPS of -$0.82 in its last earnings report, beating expectations of -$0.92. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of Soligenix Inc?
Currently, no hedge funds are holding shares in SNGX
Company Description
Soligenix Inc
Soligenix, Inc. (SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company's core sectors include biotherapeutics and public health solutions. Within biotherapeutics, it is engaged in the development of specialized drug products for oncology, inflammation, and biodefense. Soligenix's lead product candidates include SGX301, a novel photodynamic therapy for cutaneous T-cell lymphoma, and SGX942, an innate defense regulator for the treatment of oral mucositis in head and neck cancer patients.
Technical Analysis
Ownership Overview
3.95% Insiders
0.30% Mutual Funds
1.21% Other Institutional Investors
94.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---